The HAE prophylaxis class is fracturing along route of administration (one oral agent against four injectables), and 2025 brought the first oral on-demand treatment.
Hereditary angioedema (HAE) prophylaxis has moved from androgens and injectable C1-esterase inhibitor replacement to a differentiated class of targeted agents. Long-term prophylaxis now spans the subcutaneous anti-kallikrein antibody lanadelumab (Takhzyro, Takeda), the once-daily oral kallikrein inhibitor berotralstat (Orladeyo, BioCryst), subcutaneous and intravenous C1-inhibitor replacement (Haegarda and Cinryze, CSL Behring and Takeda), and two 2025 entrants: the anti-Factor XIIa antibody garadacimab (Andembry, CSL Behring, monthly) and the antisense prekallikrein-lowering agent donidalorsen (Dawnzera, Ionis, up to every eight weeks). On-demand treatment added its first oral option in July 2025: sebetralstat (Ekterly, KalVista), alongside the established injectable icatibant, ecallantide and C1-inhibitor products.
The commercial contest is now framed by route and dosing. The injectable antibodies post the largest attack-rate reductions (roughly 87% for lanadelumab and garadacimab and 81% for donidalorsen versus placebo), while oral berotralstat trades a more modest ~44% reduction for daily oral convenience. Sebetralstat directly attacks the parenteral-delay problem that has long defined on-demand care. Against an estimated US prevalence near 1 in 50,000 and a diagnosed population of roughly 6,000–10,000, HAE remains one of the most expensive US drug categories (prophylaxis routinely exceeds $300,000 per patient per year), which keeps payer management and the oral-versus-injectable switch decision at the centre of commercial strategy.
FDA-approved hereditary angioedema therapies — United States, 2026
| Drug (Brand / INN) | Class | Mechanism | Route / Dosing | US Approval | Key Trial Result |
|---|---|---|---|---|---|
| Takhzyro (lanadelumab) | Prophylaxis | Anti-plasma-kallikrein mAb | SC q2–4 wk | Aug 2018 | HELP: 0.26 vs 1.97 attacks/mo vs placebo (~87% reduction) |
| Orladeyo (berotralstat) | Prophylaxis | Oral plasma-kallikrein inhibitor | Oral once-daily | Dec 2020 | APeX-2: 1.31 vs 2.35 attacks/mo vs placebo (~44% reduction) |
| Haegarda (C1-INH, SC) | Prophylaxis | C1-esterase inhibitor replacement | SC 2×/wk | Jun 2017 | COMPACT: −3.51 attacks/mo vs placebo; ~90% response |
| Andembry (garadacimab) | Prophylaxis | Anti-Factor XIIa mAb | SC monthly | Jun 2025 | VANGUARD: 0.27 vs 2.01 attacks/mo vs placebo (−87%) |
| Dawnzera (donidalorsen) | Prophylaxis | Antisense oligonucleotide (↓ prekallikrein) | SC q4–8 wk | Aug 2025 | OASIS-HAE: 81% lower attack rate vs placebo |
| Ekterly (sebetralstat) | On-demand | Oral plasma-kallikrein inhibitor | Oral | Jul 2025 | KONFIDENT: 1.6 h median time to relief vs 6.7 h placebo |
| Firazyr / generics (icatibant) | On-demand | Bradykinin B2-receptor antagonist | SC | Aug 2011 | Established acute standard; multiple generics available |
Sources: FDA Drugs@FDA / FDA Orphan Drug database (approval status and dates); HELP, JAMA 2018 (PMID 30480729); APeX-2, J Allergy Clin Immunol 2020 (PMID 33098856); COMPACT, NEJM 2017 (PMID 28328347); VANGUARD, Lancet 2023 (PMID 36868261); OASIS-HAE, NEJM 2024 (PMID 38819395); KONFIDENT, NEJM 2024 (PMID 38819658).
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- • Attack-rate reduction across HELP, APeX-2, COMPACT, VANGUARD and OASIS-HAE • Oral vs subcutaneous vs intravenous administration and dosing interval by agent • The convenience-versus-magnitude trade-off: oral ~44% vs injectable ~81–87% attack reduction • Mechanistic segmentation: kallikrein, Factor XIIa, prekallikrein and C1-INH replacement
Delivers
- • KONFIDENT time-to-relief data for oral sebetralstat vs placebo • Positioning against injectable on-demand agents (icatibant, ecallantide, Berinert, Ruconest) • The parenteral-delay unmet need and its commercial implications • Interaction with prophylaxis: payer rules excluding concurrent acute-agent use
Delivers
- • Representative specialty-tier PA criteria: diagnosis confirmation, prescriber specialty, prior androgen/antifibrinolytic failure • ICER 2018/2021 cost-effectiveness findings and value-based benchmark discounts • Cost magnitude: >$300K/patient/yr and its effect on formulary posture • Where garadacimab, donidalorsen and sebetralstat sit without a dedicated ICER review
Custom brief delivered in 72 hours.
Commission This BriefWhat's inside
- With US prevalence near 1 in 50,000 and a diagnosed population of 6,000-10,000, HAE remains among the costliest drug categories.
- Why HAE prophylaxis routinely exceeds $300,000 per patient per year, keeping the oral-versus-injectable switch decision central to strategy.
- HELP trial data show lanadelumab cutting attack rates roughly 87% versus placebo, from 1.97 to 0.26 attacks per month.
- Why garadacimab's anti-Factor XIIa mechanism matched lanadelumab's ~87% attack reduction, while donidalorsen's antisense approach reached 81%.
- Why oral berotralstat trades a more modest ~44% attack-rate reduction for daily-pill convenience versus 81-87% for injectable antibodies.
- How the injectable antibodies lanadelumab and garadacimab post the largest attack-rate reductions in the entire prophylaxis class.
- Sebetralstat, approved July 2025, became the first oral on-demand HAE therapy, addressing the long-standing parenteral-delay problem.
- KONFIDENT trial data show sebetralstat achieving a median 1.6-hour time to relief, versus 6.7 hours for placebo.
- Representative specialty-tier PA criteria require diagnosis confirmation, prescriber specialty, and documented prior androgen or antifibrinolytic failure.
- Why garadacimab, donidalorsen, and sebetralstat entered the market in 2025 without a dedicated ICER cost-effectiveness review.
- AXLRx sources the ICER 2018 Final Evidence Report and its 2021 real-world-evidence update for cost-effectiveness benchmarks in HAE.
- Why garadacimab, donidalorsen, and sebetralstat, all approved in 2025, still await a dedicated ICER value assessment.
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx brief is built from primary regulatory sources (FDA Drugs@FDA and the FDA Orphan Drug database, ClinicalTrials.gov), peer-reviewed literature, and live payer policy documentation — not secondary summaries, market-research reports, or unverified estimates. Findings are independently verified before inclusion; if a figure cannot be sourced to a live record, it does not ship.
US Hereditary Angioedema Competitive Intelligence sources: FDA Drugs@FDA and the FDA Orphan Drug database (approval status and dates), primary trial publications in JAMA, the New England Journal of Medicine, the Lancet and the Journal of Allergy and Clinical Immunology (HELP, APeX-2, COMPACT, VANGUARD, OASIS-HAE, KONFIDENT), ClinicalTrials.gov pipeline registrations, US payer coverage policies, and the ICER 2018 Final Evidence Report and 2021 real-world-evidence update.
- Prophylaxis efficacy verified against primary publications: HELP (PMID 30480729), APeX-2 (PMID 33098856), COMPACT (PMID 28328347), VANGUARD (PMID 36868261), OASIS-HAE (PMID 38819395)
- Oral on-demand time-to-relief verified against KONFIDENT, NEJM 2024 (PMID 38819658)
- FDA approval status and dates verified against FDA Drugs@FDA and the FDA Orphan Drug database
- Cost-effectiveness figures verified against the ICER 2018 Final Evidence Report and 2021 real-world-evidence update
Frequently asked questions
Commission this brief
AXLRx delivers US hereditary angioedema competitive intelligence built for pharma and biotech commercial, access, and medical affairs teams. Custom brief in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified brief in 72 hours with optional analyst readout.